Involvement of patients and consumers in the Agency's activities
Patients and consumers are the end-users of the medicines that the European Medicines Agency evaluates, so they are key stakeholders with specific knowledge and expertise to offer the Agency.
The Agency is committed to maintaining a strong working relationship with patients and consumers and is interacting with a growing number of patients’ and consumers’ organisations.
See more information on the Agency's work with patients and consumers.
Searching for medicines by therapeutic area
It is possible to browse for a medicine by therapeutic area. The Agency categorises each medicine it assesses using a taxonomy which can be easily browsed. Go to European public assessment reports (EPARs) and use the 'browse by therapeutic area' tab.
Beware of falsified medicines!
Falsified medicines are fake medicines that may enter the supply chain illegally. Be careful about the way you buy medicines. Find more information on falsified medicines.
Search for herbal medicines
The Agency is responsible for supporting the harmonisation of herbal medicinal products in Europe. Search for herbal medicines assessed by the Agency's Committee on Herbal Medicinal Products.
News for patients and carers
The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) concluded two safety reviews and gave a recommendation as part of a regular benefit-risk assessment review of a medicine at its July meeting. ... Read more
Registration opens for workshop on clinical trial design in neuromyelitis optica to facilitate global medicine development in a rare and serious disease
Registration is now open for a regulatory workshop on clinical trial design in neuromyelitis optica and spectrum disorders at the European Medicines Agency on 10 October 2014. ... Read more
Management Board delays formal adoption of EMA publication of clinical trial data policy to October 2014
The Management Board of the European Medicines Agency (EMA) has postponed formal adoption of the policy on publication of clinical trial data to its 2 October 2014 meeting. ... Read more
This page provides an overview of the opinions adopted at the June 2014 meeting of the Committee for Medicinal Products for Human Use (CHMP) and other important outcomes. ... Read more
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Daklinza (daclatasvir) in combination with other medicines for the treatment of chronic (long-term) hepatitis C virus (HCV) infection in adults. ... Read more
- See all News for patients and carers
Events of interest
This event aims to promote communication between national competent authorities and patient and healthcare-professional organisations, providing an overview on the latest norms and guidelines on clinical trials and an introduction to the pharmacovigilance legislation. It aims to serve also as a platform for networking between local organisations and authorities in order to promote further activities and cooperation. It is supported by the European Commission and organised in collaboration with the Medicines and Medical Devices Agency of Serbia as a final event prior the closure of the Instrument for Pre-accession I Programme. Registration by invitation only. ... Read more
Committee for Advanced Therapies (CAT) and the German Society for Transfusion Medicine and Immunohaematology (DGTI) workshop on advanced-therapy medicinal products: How to bring cell-based medicinal products successfully to the market
The workshop is co-organised by the European Medicines Agency's (EMA's) Committee for Advanced Therapies (CAT) and the German Society for Transfusion Medicine and Immunohaematology (DGTI) in collaboration with the German Stem Cell Network (GSCN) and aims to strengthen dialogue between CAT and the advanced-therapy-medicinal-product (ATMP) developers in industry, academia and hospitals and to facilitate ATMP development and access to the registration procedure. The workshop will allow for the attendees to learn about the development and authorisation of cell-based ATMPs in the European Union and the role of the CAT; to learn about the support provided by EMA and the CAT to ATMP developers; to understand the criteria that CAT applies for the classification of ATMPs; and to hear about CAT’s considerations and recent interactions with experts on cell-based therapies for cardiac repair. It will also allow to interact directly with the Regulators in an open forum discussion. ... Read more
04/12/2014 - 05/12/2014
European Medicines Agency (EMA)/European Federation of Pharmaceutical Industries and Associations (EFPIA) workshop on the importance of dose finding and dose selection for the successful development, licensing and lifecycle management of medicinal products
A European Medicines Agency (EMA)/European Federation of Pharmaceutical Industries and Associations (EFPIA) workshop is planned for 4-5 December 2014 to discuss the importance of dose finding and dose selection for the successful development, licensing and lifecycle management of medicinal products. Registration: please register by 19 September 2014 using the registration form provided. ... Read more
13/10/2014 - 17/10/2014
European Medicines Agency excellence in pharmacovigilance: Clinical trials and post-marketing training course
This course is designed to provide a firm grounding in key aspects of global and mainly European clinical pre- and post-marketing safety regulatory requirements. This five-day training course now also includes highlights and updates on the implementation of the new pharmacovigilance legislation and the latest news on the international harmonisation and standardisation activities in pharmacovigilance. Places limited. ... Read more
The aim of this workshop is to address the needs and priorities for Pharmacovigilance in the paediatric population. The objectives are to outline the current work performed at the EMA with regard to paediatric safety, and to discuss the potential for improvement in terms of active paediatric Pharmacovigilance. ... Read more
- See all Events of interest